Lazard Asset Management
SYRE icon

Lazard Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Lazard Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-352
Closed -$69K – 2455
2021
Q3 		$69K Buy
+352
New +$61.6K ﹤0.01% 1541

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Lazard Asset Management's SYRE Position: Q4 2021 in Review

Lazard Asset Management sold out of Spyre Therapeutics (SYRE) in Q4 2021, closing a stake of 352 shares — an estimated $69K sold.

Lazard Asset Management first reported a position in SYRE in Q3 2021 and held it in 1 quarter. The position peaked at $69K in Q3 2021. 85 funds tracked by Wall St. Rank hold SYRE as of Q4 2021.

  • Lazard Asset Management reported no remaining Spyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Lazard Asset Management sold 352 Spyre Therapeutics shares in Q4 2021, an estimated $69K.
  • Lazard Asset Management first reported a position in Spyre Therapeutics in Q3 2021 and held it in 1 quarter.
  • Lazard Asset Management's Spyre Therapeutics position peaked at $69K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2021.

Based on Lazard Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.